LC–ESI-MS method for the determination of bisoprolol in human plasma

Ding, Li; Zhou, Xin; Guo, Xiao‐Feng; Song, Qinxin; He, Juan; Xu, Gelin

doi:10.1016/j.jpba.2007.03.001

Cited by 35 publications

(25 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical pharmacokinetic data for both intravenous and oral administration of bisoprolol in healthy adults and patients with impaired renal function were obtained from the literature [10,[15][16][17] . The pharmacokinetic studies after intravenous administration of bisoprolol at two doses were conducted in 8 Western female subjects (age 25±3 years) [15] and 12 Western male subjects (age 37±12 years) [16] , respectively.…”

Section: Clinical Pharmacokinetic Datamentioning

confidence: 99%

“…The pharmacokinetic studies after intravenous administration of bisoprolol at two doses were conducted in 8 Western female subjects (age 25±3 years) [15] and 12 Western male subjects (age 37±12 years) [16] , respectively. The pharmacokinetic studies following single oral administration of 5, 10, and 20 mg of bisoprolol were conducted in 18 Asian male subjects (age 22±1 years) [17] , 12 Western male subjects (age 37±12 years) [16] , and 5 Western male subjects (age 53±3 years [16] , respectively. Mean data in the aforementioned publications were captured by computer digitization and used for development and validation of the WB-PBPK model.…”

Section: Clinical Pharmacokinetic Datamentioning

confidence: 99%

See 1 more Smart Citation

Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

Wang

Chen

et al. 2012

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: To develop and evaluate a whole-body physiologically based pharmacokinetic (WB-PBPK) model of bisoprolol and to simulate its exposure and disposition in healthy adults and patients with renal function impairment. Methods: Bisoprolol dispositions in 14 tissue compartments were described by perfusion-limited compartments. Based the tissue composi tionequationsanddrug-specificpropertiessuchaslogP,permeability,andplasmaproteinbindingpublishedinliteratures, the absorption and whole-body distribution of bisoprolol was predicted using the 'Advanced Compartmental Absorption Transit' (ACAT) model and the whole-body disposition model, respectively. Renal and hepatic clearances were simulated using empirical scaling methodsfollowedbyincorpora tionintotheWB-PBPKmodel.Modelrefinementswereconductedafteracomparisonofthesimulated concentration-timeprofilesandpharmacokineticparameterswiththeobserveddatainhealthyadultsfollowingintravenousandoral administration. Finally, the WB-PBPK model coupled with a Monte Carlo simulation was employed to predict the mean and variability of bisoprolol pharmacokinetics in virtual healthy subjects and patients. Results: The simulated and observed data after both intravenous and oral dosing showed good agreement for all of the dose levels in the reported normal adult population groups. The predicted pharmacokinetic parameters (AUC, C max , and T max ) were reasonably consistent(<1.3-folderror)withtheobservedvaluesaftersingleoraladministrationofdosesrangingfromof5to20mgusingtherefined WB-PBPKmodel.Thesimulatedplasmaprofilesaftermultipleoraladministrationofbisoprololinhealthyadultsandpatientwithrenal impairmentmatchedwellwiththeobservedprofiles. Conclusion:The WB-PBPK model successfully predicts the intravenous and oral pharmacokinetics of bisoprolol across multi ple dose levelsindiversenormaladulthumanpopulationsandpatientswithrenalinsufficiency.

show abstract

Section: Clinical Pharmacokinetic Datamentioning

confidence: 99%

Section: Clinical Pharmacokinetic Datamentioning

confidence: 99%

Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

Wang

Chen

et al. 2012

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…butendioate is a competitive beta (1) -selective adrenergic antagonist [1]. Hydrochlorothiazide (HCTZ), is 6-chloro-3, 4-dihydro-7-sulfamoyl-2H-1, 2, 4-benzothiadizine 1, 1-dioxide (5) [e] is a benzothiadiazine diuretc [2].…”

Section: Bisoprolol Fumarate (Bf) (+/-) -1-(4-((2-(-methyl Ethoxy) Ementioning

confidence: 99%

Development and Validation of TLC-Densitometry Method for Simultaneous Estimation of Bisoprolol Fumarate and Hydrochlorothiazide in Bulk and Tablets

Bhoya¹

2012

J Chromat Separation Techniq

View full text Add to dashboard Cite

A new simple, precise, accurate and selective TLC-densitometry method has been developed for simultaneous determination of bisoprolol fumarate and hydrochlorothiazide in tablet dosage form. Chromatographic separation was performed on aluminum plate precoated with silica gel 60F254, using chloroform: ethanol: glacial acetic acid fumarate and hydrochlorothiazide were 0.62 and 0.40, respectively. The reliability of the method was assessed by evaluation of linearity which was found to be 200-1200 ng/spot for bisoprolol fumarate and 100-800 ng/spot for hydrochlorothiazide. Accuracy of the method was accessed by % recovery and found to be 100.02 ± 1.14% for bisoprolol fumarate and 99.91 ± 0.96% for hydrochlorothiazide. The method can be used for routine analysis of bisoprolol fumarate and hydrochlorothiazide in tablet dosage form.

show abstract

“…Several analytical methods have been studied for the determination of BIS in biological fluids. Among these methods, HPLC (Joshi et al, 2010;Tutunji et al, 2009;Shaikh et al, 2008;Patel et al, 2006), LC-MS-MS (Peste et al, 2010;Ding et al, 2007;Caudron et al, 2004) have been utilized for the determination of BIS. Some methods have also been reported for the determination of BIS in pharmaceutical preparations.…”

Section: Introductionmentioning

confidence: 99%

Application of Bromocresol Green and Bromothymol Blue for the Extractive Spectrophotometric Determination of Anti-hypertensive Drugs

El‐Didamony¹,

Hafeez²,

Saad³

2015

J App Pharm Sci

View full text Add to dashboard Cite

Simple, selective and highly sensitive spectrophotometric methods are proposed for the rapid and accurate determination of anti-hypertensive drugs namely telmisartan (TEL), propranolol (PRO), bisoprolol (BIS) and carvedilol (CRV) in tablets and biological fluids using bromocressol green (BCG) and bromothymol blue (BTB). The developed methods involve formation of stable yellow colored dichloromethane extractable ion-pair complexes of the amino derivative of four antihypertensive drugs such as TEL, PRO, BIS and CRV with two sulphonphthalein acid dyes, namely; BCG and BTB in acidic buffer. The effect of optimum conditions via pH on the ion-pair formation, reagent concentration, time and temperature and solvent was studied. The composition of the ion-pairs was found 1: 1 by Job's method. The established methods having high sensitivity and good selectivity could be applied to the determination of the studied drugs in pharmaceutical, urine and blood serum samples with satisfactory results. The results obtained are good agreement with experimental data. The reaction mechanism was also discussed.

show abstract

LC–ESI-MS method for the determination of bisoprolol in human plasma

Cited by 35 publications

References 5 publications

Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

Development and Validation of TLC-Densitometry Method for Simultaneous Estimation of Bisoprolol Fumarate and Hydrochlorothiazide in Bulk and Tablets

Application of Bromocresol Green and Bromothymol Blue for the Extractive Spectrophotometric Determination of Anti-hypertensive Drugs

Contact Info

Product

Resources

About